目的:系统评价荆花胃康胶丸联合三联疗法治疗幽门螺杆菌(Hp)相关性慢性胃炎或消化性溃疡的有效性和安全性,为临床提供循证参考。方法:计算机检索Medline、PubMed、Embase、ISI Web of Science、中国知网、万方等数据库,收集荆花胃康胶...目的:系统评价荆花胃康胶丸联合三联疗法治疗幽门螺杆菌(Hp)相关性慢性胃炎或消化性溃疡的有效性和安全性,为临床提供循证参考。方法:计算机检索Medline、PubMed、Embase、ISI Web of Science、中国知网、万方等数据库,收集荆花胃康胶丸联合三联疗法对比三联疗法或联用铋剂的四联疗法治疗Hp相关性慢性胃炎或消化性溃疡的随机对照试验(RCT),筛选文献、提取资料,采用改良的Jadad量表评价文献质量,并采用RevMan 5.0软件进行Meta分析。结果:共纳入22项RCT,包含3 069例患者。Meta分析结果显示,相比三联疗法组,荆花胃康胶丸+三联疗法组在Hp根除率[OR=1.96,95%CI(1.47,2.60),P<0.001]、消化道症状缓解率[OR=1.75,95%CI(1.27,2.41),P<0.001]方面更优,差异均有统计学意义,但不良反应发生率与之比较差异无统计学意义[OR=0.67,95%CI(0.36,1.25),P=0.21];荆花胃康胶丸+三联疗法组患者的Hp根除率[OR=0.97,95%CI(0.75,1.26),P=0.83]、消化道症状缓解率[OR=1.37,95%CI(0.97,1.94),P=0.07]与四联疗法组比较,差异均无统计学意义,但荆花胃康胶丸+三联疗法组患者的不良反应发生率显著低于后者,差异有统计学意义[OR=0.25,95%CI(0.15,0.44),P<0.001]。结论:荆花胃康胶丸联合三联疗法相比三联疗法能显著提高患者Hp根除率和消化道症状缓解率,相比四联疗法能显著降低其不良反应发生率。展开更多
Objective： To investigate the bactericidal effects of Jinghua Weikang Capsule （荆花胃康胶丸） and its major component Chenopodium ambrosioides L. on antibiotic-resistant Helicobacter pylori. Methods： Four clinical ...Objective： To investigate the bactericidal effects of Jinghua Weikang Capsule （荆花胃康胶丸） and its major component Chenopodium ambrosioides L. on antibiotic-resistant Helicobacter pylori. Methods： Four clinical antibiotic-resistant H. pylori strains were isolated and incubated in liquid medium containing Jinghua Weikang Capsule or Chenopodium ambrosioides L. By means of time-kill curve method, the average colony counts and bactericidal rate were calculated at time points of 0, 4, 8 and 24 h after the incubation and the time-kill curves were charted. Results： Both Jinghua Weikang Capsule and Chenopodium ambrosioides L. at a concentration of 0.64 g/L showed obvious bactericidal effect against antibiotic-resistant H. pylori after 4 h of incubation. Conclusion： Jinghua Weikang Capsule and Chenopodium ambrosioides L. are considered to be active against antibiotic-resistant H. pylori in vitro.展开更多
文摘目的:系统评价荆花胃康胶丸联合三联疗法治疗幽门螺杆菌(Hp)相关性慢性胃炎或消化性溃疡的有效性和安全性,为临床提供循证参考。方法:计算机检索Medline、PubMed、Embase、ISI Web of Science、中国知网、万方等数据库,收集荆花胃康胶丸联合三联疗法对比三联疗法或联用铋剂的四联疗法治疗Hp相关性慢性胃炎或消化性溃疡的随机对照试验(RCT),筛选文献、提取资料,采用改良的Jadad量表评价文献质量,并采用RevMan 5.0软件进行Meta分析。结果:共纳入22项RCT,包含3 069例患者。Meta分析结果显示,相比三联疗法组,荆花胃康胶丸+三联疗法组在Hp根除率[OR=1.96,95%CI(1.47,2.60),P<0.001]、消化道症状缓解率[OR=1.75,95%CI(1.27,2.41),P<0.001]方面更优,差异均有统计学意义,但不良反应发生率与之比较差异无统计学意义[OR=0.67,95%CI(0.36,1.25),P=0.21];荆花胃康胶丸+三联疗法组患者的Hp根除率[OR=0.97,95%CI(0.75,1.26),P=0.83]、消化道症状缓解率[OR=1.37,95%CI(0.97,1.94),P=0.07]与四联疗法组比较,差异均无统计学意义,但荆花胃康胶丸+三联疗法组患者的不良反应发生率显著低于后者,差异有统计学意义[OR=0.25,95%CI(0.15,0.44),P<0.001]。结论:荆花胃康胶丸联合三联疗法相比三联疗法能显著提高患者Hp根除率和消化道症状缓解率,相比四联疗法能显著降低其不良反应发生率。
基金Supported by Capital Medical Development and Research Foundation(No.SF-2007-Ⅲ-01)National Natural Science Foundation of China(No.8107295)
文摘Objective： To investigate the bactericidal effects of Jinghua Weikang Capsule （荆花胃康胶丸） and its major component Chenopodium ambrosioides L. on antibiotic-resistant Helicobacter pylori. Methods： Four clinical antibiotic-resistant H. pylori strains were isolated and incubated in liquid medium containing Jinghua Weikang Capsule or Chenopodium ambrosioides L. By means of time-kill curve method, the average colony counts and bactericidal rate were calculated at time points of 0, 4, 8 and 24 h after the incubation and the time-kill curves were charted. Results： Both Jinghua Weikang Capsule and Chenopodium ambrosioides L. at a concentration of 0.64 g/L showed obvious bactericidal effect against antibiotic-resistant H. pylori after 4 h of incubation. Conclusion： Jinghua Weikang Capsule and Chenopodium ambrosioides L. are considered to be active against antibiotic-resistant H. pylori in vitro.
